Rodon Ahnert and his team released the Phase I clinical trial data of HMPL-306 (Ranosidenib), which targeted patients with IDH-mutated gliomas and other solid tumors in Western populations [142]. This evidence concerns the gene IDH1 and central nervous system cancer.